Holders Of Acer Therapeutics Stock Since At Least September 25, 2017

Acer Therapeutics Investors Who Have Held Their Stock Continuously Since At Least September 25, 2017 Are Encouraged To Contact Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is investigating potential breaches of fiduciary duty claims involving certain officers and/or directors of Acer Therapeutics, Inc. (“Acer” or the “Company”) (NASDAQ: ACER).

The investigation concerns, among other things, whether certain Acer officers and/or directors made materially false and misleading statements and/or failed to disclose material information regarding, among other things, the Company’s business, operational, and compliance policies and whether Acer lacked sufficient data to support filing EDSIVO’s (celiprolol) New Drug Application (“NDA”) with the FDA for the treatment of Ehlers-Danlos Syndrome (“vEDS”).

Investors who have owned Acer stock continuously since at least September 25, 2017 are encouraged to contact Kehoe Law Firm, P.C., Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected], [email protected], to discuss the investigation or potential legal claims.

Kehoe Law Firm, P.C.